Få 200 $ for at oprette en Interactive Brokers-konto med vores link: Opret IBKR-konto. Læs vores analyse af Interactive Brokers

Ticker
AZT.OL

Price
22.00
Stock movement down
-0.30 (-1.29%)
Company name
Arcticzymes Technologies ASA
Exchange
(OL
,
Currency
NOK
)
Sector
Healthcare >
Biotechnology
Markedsværdi
1.17B
Ent værdi
1.01B
Pris/omsætning
11.40
Pris/bog
3.55
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
153.41
Fremtidig P/E
57.19
PEG
-
EPS-vekst
-
1 års afkast (CAGR)
22.34%
3 års afkast (CAGR)
-17.51%
5 års afkast (CAGR)
-21.39%
10 års afkast (CAGR)
7.85%
Senest opdateret: 2026-02-26

UDBYTTE

AZT.OL betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E153.41
Pris til OCF62.42
Pris til FCF185.83
Pris til EBITDA164.08
EV i forhold til EBITDA141.76

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning11.40
Pris til egenkapital3.55
EV i forhold til salg9.85

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier51.07M
EPS (TTM)0.15
FCF pr. aktie (TTM)0.12

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)103.07M
Bruttofortjeneste (TTM)98.36M
Driftsindkomst (TTM)-2.62M
Nettoindkomst (TTM)7.66M
EPS (TTM)0.15
EPS (1 år frem)0.40

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)95.42%
Driftsmargin (TTM)-2.54%
Fortjenstmargin (TTM)7.43%

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter182.30M
Nettotilgodehavender13.34M
Omsætningsaktiver i alt296.13M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr18.35M
Sum aktiver352.97M
Kreditor4.07M
Kortfristet/nuværende langsigtet gæld0.00
Summen af kortfristede forpligtelser18.11M
Sum gæld22.50M
Aktionærernes egenkapital330.48M
Materielle nettoaktiver0.00

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)18.82M
Investeringsudgifter (TTM)12.50M
Fri pengestrøm (TTM)6.32M
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast2.32%
Afkast af aktiver2.17%
Afkast af investeret kapital2.32%
Kontant afkast af investeret kapital1.91%

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning23.20
Daglig høj23.50
Daglig lav22.70
Daglig volumen45K
Højeste gennem alle tider111.00
1 års analytiker estimat31.50
Beta0.35
EPS (TTM)0.15
Udbytte pr. aktie0.00
Ex-div dato-
Næste dato for resultatpræsentation6 May 2026

Nedsidepotensial

Loading...
Nedsidepotensial-data
AZT.OLS&P500
Nuværende prisfald fra top notering-80.18%-1.82%
Højeste prisfald-93.51%-56.47%
Højeste efterår dato21 Dec 20099 Mar 2009
Gennemsnitlig fald fra toppen-66.51%-10.84%
Gennemsnitlig tid til nyt højdepunkt113 days12 days
Maks. tid til nyt højdepunkt3360 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
AZT.OL (Arcticzymes Technologies ASA) company logo
Markedsværdi
1.17B
Markedsværdi kategori
Small-cap
Beskrivelse
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Personale
53
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
Norway
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activi...
27. januar 2026
As the European market navigates a landscape of mixed economic signals and resilient earnings results, the pan-European STOXX Europe 600 Index has shown modest gains, reflecting cautious optimism amon...
19. januar 2026
Amidst a mixed performance in major European stock indexes, with the STOXX Europe 600 Index ending slightly higher due to resilient economic data and earnings results, investors are keenly observing o...
19. januar 2026
As the European markets experience a wave of optimism with major indexes like the STOXX Europe 600 Index climbing 2.27%, investors are keenly observing opportunities that may be trading below their fa...
13. januar 2026
Amid optimism about the European economy and favorable interest rate conditions, major stock indexes across the region have experienced gains, with Germany's DAX and France's CAC 40 Index showing nota...
13. januar 2026
As the pan-European STOXX Europe 600 Index reaches new highs, buoyed by an improving economic environment and closing 2025 with its strongest yearly performance since 2021, investors are increasingly ...
9. januar 2026
As the European markets continue to flourish, with the STOXX Europe 600 Index reaching new highs and closing out 2025 with its strongest annual performance since 2021, investors are keenly eyeing stoc...
9. januar 2026
As the European markets continue to show strength, with the STOXX Europe 600 Index reaching new highs and closing 2025 with its best performance in years, investors are keenly observing opportunities ...
7. januar 2026
Amidst a buoyant economic environment, the European markets have experienced notable gains, with the STOXX Europe 600 Index reaching new highs and major indices like Germany's DAX and France's CAC 40 ...
7. januar 2026
ArcticZymes Technologies ASA (LTS:0DRV) reports a 24% revenue increase and strategic initiatives for future expansion despite challenges in key markets.
6. november 2025
Næste side